Physician profile
Bao Yang
NPI 1154723500
$3,509.74
in general payments reported to CMS, 2019-2025
20 companies · $1,078 in 2025
The $1,078 reported for 2025 was more than what 82% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12.66 · 2022: $217 · 2023: $1,108 · 2024: $1,095 · 2025: $1,078.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,619 · Education: $661.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,619.16 |
| Education | $660.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $675.04 | 2022-2025 | Tremfya |
| Abbvie INC. | $614.28 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $335.82 | 2022-2025 | Dupixent, Libtayo |
| E.R. Squibb & Sons, L.L.C. | $289.13 | 2022-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $275.90 | 2023-2025 | Winlevi, Absorica Ld, Ilumya |
| Incyte Corporation | $246.96 | 2023-2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $156.63 | 2023-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $131.56 | 2022-2025 | |
| Ucb, INC. | $119.46 | 2024-2025 | Bimzelx |
| Galderma Laboratories, L.P. | $112.98 | 2022-2025 | Nemluvio, Aklief |
| Almirall LLC | $106.13 | 2023-2025 | Klisyri, Seysara |
| Pfizer INC. | $79.31 | 2023-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $73.96 | 2024-2025 | Cabtreo, Jublia, Arazlo |
| Lilly USA, LLC | $63.19 | 2023-2024 | Taltz, Olumiant |
| Amgen INC. | $54.31 | 2021-2023 | Otezla |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verrica Pharmaceuticals INC. | $49.34 | 2024-2025 | Ycanth |
| Leo Pharma INC. | $43.12 | 2024-2025 | Adbry |
| Mayne Pharma Commercial LLC | $30.23 | 2025 | |
| Tg Therapeutics, INC. | $27.92 | 2025 | |
| Dermavant Sciences, INC. | $24.47 | 2023 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bao Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.